Nonalcoholic Steatohepatitis (NASH) is a growing concern globally, with its prevalence on the rise due to sedentary lifestyles and poor dietary habits. Understanding the intricacies of NASH is crucial for developing effective treatments, and researchers are increasingly turning to in vitro models to unravel the mysteries of this complex liver disease.
In recent years, the spotlight...
The advent of AI technology has revolutionized several sectors, one of which is drug development and validation. The potential of AI technology in informing the processes such as the development of antibodies and optimizing molecules is progressively substantial. AI technology has made it easier, faster, and more accurate to train models, validate antibodies, and optimize molecules for drug...
AAV design for gene replacement
In gene replacement therapy, the AAV delivery system is critical to the expression of the transgene in target cells. Currently, AAV-based gene replacement strategies have been developed to treat retinal degeneration. The results indicate that AAV plays an important role in repairing retinal function and photoreceptor structure in a wide collection of animal...
Adeno-associated virus (AAV) is a prominent gene therapy delivery vehicle abundantly used in clinical trials worldwide. However, the restricted cell and tissue tropism of many of the serotypes limit their applicability to treating multisystem diseases. To overcome these limitations, Creative Biolabs offers high-quality AAV capsid modification services to promote the development of global...
Working in the field of gene therapy for years, Creative Biolabs has developed a full package of techniques for AAV biodistribution and shedding analysis. With professional scientists, we can assess specific AAV vector distribution at different levels, including but not limited to organism level, tissue level, as well as the cellular level. The AAV biodistribution and shedding analysis services...
Genetically modified T cell
Genetically modified TCR therapy is based on altering the specificity of T cells by expressing specific TCR α and β chains, which mediate antigen recognition. The tumor-specific TCR α and β chains were recognized, isolated and cloned into the transduction vector, and the transduction of T cells produced tumor antigen-specific T cells.
Cancer vaccine animal models
For tumor vaccines, traditional animal models for toxicity evaluation usually provide limited information, especially for human-specific antigens targeted. Creative Biolabs is dedicated to establishing the most suitable animal models for cancer vaccine development including pre-clinical pharmacology services and pre-clinical toxicology...
anti-CD20 CAR-T in vivo assay
We have successfully developed various animal models for the in vivo assay of anti-CD 20 CAR-T cell therapy. Immunodeficiency mice are injected intravenously, subcutaneously, or intraperitoneally with CD20+ cells, such as lymphoma cell lines, CD20 transfected cell lines, human primary lymphoma cells, as well as customized cell lines to build up a murine...
The field of antibody development has witnessed significant advancements, particularly with the emergence of novel strategies in hapten design. Haptens, small molecules that can elicit an immune response, play a pivotal role in generating antibodies with high specificity and affinity. This article explores the impact of anti-hapten design on antibody development, with a focus on the design and...
Macrophages, integral components of the immune system, play a crucial role in maintaining homeostasis and combating infections. In recent years, researchers have uncovered the diverse applications of macrophages in disease treatment research.
Atherosclerosis, a leading cause of cardiovascular diseases, involves the accumulation of plaques within arterial walls. Macrophages contribute...
The field of cancer research has been remarkably transformed in recent years, with a significant emphasis placed on the potential of immunotherapy. Central to these advancements has been a unique subset of immune cells known as gammadelta (γδ) T cells. These T cells are gaining attention due to their innate ability to detect and destroy tumor cells. Additionally, they can be...
PD-L1 therapy is an innovative treatment modality in the field of cancer immunotherapy. It works by blocking the interaction between the programmed cell death protein (PD-1) and its ligand (PD-L1), essentially reinvigorating the body’s immune system to attack cancer cells. Notable for its application in treating various cancers, such as lung cancer, kidney cancer, and melanoma, PD-L1...
Many attempts have been made recently to discover PD-1 inhibitors for treating different kinds of tumors, including but not limited to advanced melanoma and non-small cell lung cancer (NSCLC). The clinical data have shown that these antibodies targeting PD-1 and its ligand PD-L1 can block the activation of T cells and induce anti-tumor activities to improve patients' outcomes in the clinic.
The clinical data have shown that these antibodies targeting PD-1 and its ligand PD-L1 can block the activation of T cells and induce anti-tumor activities to improve patients' outcomes in the clinic. Nowadays, several small-molecules PD-1/PD-L1 drug-like inhibitors have been developed for the treatment of many cancers.
Immune Checkpoint PD-1 for Drug Development
In the past few years, immune checkpoints have shown a promising role in treating various diseases, including cancers. The immune checkpoint drugs are usually designed by blocking or inhibiting the signal pathways of T cells or B cells, thus achieving resistance to diseases. A wide variety of immune checkpoint molecules, such as PD-1/PD-L1, are...
Parasites are notorious for inflicting a broad spectrum of illnesses, often leaving catastrophic health impacts on their hosts. These microorganisms pose a major threat to global health, contributing significantly to the burden of diseases around the world. The discovery of parasite antibodies, therefore, is a pivotal breakthrough. It potentially provides researchers and medical practitioners...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian